Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy

Lanza, Carlo; Romano, Marco; Cortés Castan, Javier; de las Heras, Begoña; Saini, Kamal S.; de Azambuja, Evandro

View

Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy, 2020 (273.1Kb)

Author

Lanza, Carlo

Romano, Marco

Cortés Castan, Javier

de las Heras, Begoña

Saini, Kamal S.

de Azambuja, Evandro

Date

2020-09

Permanent link

https://hdl.handle.net/11351/6429

DOI

10.1038/s41416-020-0948-x

ISSN

1532-1827

WOS

000542071100001

PMID

32572174

Show full item record

Abstract

Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.

Keywords

Drug development; Viral infection

Bibliographic citation

Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. Br J Cancer. 2020 Sep;123:694–697.